Ning Fan

Dr. Ning Fan

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2020 in Molecular Therapy - Methods & Clinical Development
Verified
Journal Article
Open access
JTJunkai Tan
Junkai Tan
XZXiaoguang Zhang
Xiaoguang Zhang
DLDanli Li
Danli Li
GLGuo Liu
Guo Liu
YWYun Wang
Yun Wang
NFNing Fan
Ning Fan
Glaucoma is characterized by retinal ganglion cell (RGC) death and axonal loss. Therefore, neuroprotection is important in treating glaucoma. In this study, we explored whether exoenzyme C3 transferase (C3)-based gene therapy could protect retinas in an ischemia/reperfusion (I/R) injury rat model. Self-complementary adeno-associated virus 2 (scAAV2) vectors encoding either C3 protein (scAAV2-C3) or enhanced green fluorescence protein (scAAV2-EGFP) were intravitreally delivered into both eyes of rats, and I/R models (acute ocular hypertension) were made in one eye of each rat at day 7 after the injection. The rats were divided into six groups: scAAV2-C3, scAAV2-C3 with I/R, scAAV2-EGFP, scAAV2-EGFP with I/R, blank control, and blank control with I/R. TUNEL (terminal deoxynucleotidyltransferase-mediated deoxyuridine triphosphate nick end labeling), immunohistochemistry of cleaved caspase-3, NeuN and Brn-3a, and H&E staining were used to detect apoptotic cells and other changes in the retina. The results showed that scAAV2-C3 significantly reduced the number of apoptotic RGCs and decreased cell loss in the ganglion cell layer after I/R injury, and the I/R-injured retinas treated with scAAV2-C3 were the thickest in all I/R groups. These results suggest that scAAV2-mediated C3 gene therapy is able to protect the rat retina from I/R injury and has potential in the treatment of glaucoma in the future.

1 September 2021 in Experimental Eye Research
Verified
Journal Article
Closed access
CLChunlin Lan
Chunlin Lan
JTJunkai Tan
Junkai Tan
LTLi Tang
Li Tang
GLGuo Liu
Guo Liu
LHLongxiang Huang
Longxiang Huang
NFNing Fan
Ning Fan

14 May 2025 in Advanced Science
Verified
Journal Article
Open access
HWHuide Wang
Huide Wang
CWChen Wang
Chen Wang
YZYule Zhang
Yule Zhang
ZWZiqian Wang
Ziqian Wang
YZYihan Zhu
Yihan Zhu
MQMeng Qiu
Meng Qiu
In recent years, monoelemental 2D materials (Xenes) such as graphene, graphdiyne, silicene, phosphorene, and tellurene, have gained significant traction in biosensing applications. Owing to their ultra‐thin layered structure, exceptionally high specific surface area, unique surface electronic properties, excellent mechanical strength, flexibility, and other distinctive features, Xenes are recognized for their potential as materials with low detection limits, high speed, and exceptional flexibility in biosensing applications. In this review, the unique properties of Xenes, their synthesis, and recent theoretical and experimental advances in applications related to biosensing, including DNA/RNA biosensors, protein biosensors, small molecule biosensors, cell, and ion biosensors are comprehensively summarized. Finally, the challenges and prospects of this emerging field are discussed.

24 May 2025 in Journal of Glaucoma
Verified
Journal Article
Closed access
YSYunhe Song
Yunhe Song
XYXiangxiang Ye
Xiangxiang Ye
MYMingmin Yang
Mingmin Yang
ZZZhihong Zhang
Zhihong Zhang
LZLiuzhi Zeng
Liuzhi Zeng
LTLiming Tao
Liming Tao
Précis: Phacogoniotomy, a combination of phacoemulsification and intraocular lens implantation (PEI) and 120-degree goniotomy (GT), was an effective and safe surgical treatment for medically controlled or uncontrolled primary open angle glaucoma (POAG) with cataract. Purpose: To evaluate the efficacy and safety of PEI combined with 120-degree GT in the treatment of medically controlled or uncontrolled POAG with cataract. Methods: Multicenter observational study conducted in 9 ophthalmic institutes/general hospitals in China. Patients with medically controlled [baseline intraocular pressure (IOP) ≤21 mmHg] or uncontrolled (baseline IOP > 21 mmHg) POAG with clinically significant cataract were included, who were followed up with at least 12 months. The IOP, topical hypotensive medication, surgery complications, visual acuity, surgery success were recorded and compared between groups at baseline and the final visit. Complete surgical success was defined as postoperative IOP of 5–18 mmHg without additional topical medications, vision-threatening complications or reoperation for glaucoma. Qualified success is same as complete success except allowing use of ocular hypotensive medications. Results: One hundred participants with 132 eyes were included with a mean follow-up time of 17.5±5.2 months ( range:12–32) postoperatively. In general, the mean IOP reduced from 21.2±7.4 mmHg at baseline to 14.7±2.9 mmHg postoperatively (P0.05), respectively. Conclusion: POAG with cataract could be effectively treated by phacogoniotomy, regardless of medically controlled or medically uncontrolled status at baseline.

20 November 2023 in Ophthalmology and Therapy
Verified
Journal Article
Open access
PDF file
MYMingmin Yang
Mingmin Yang
XPXiaohua Pan
Xiaohua Pan
ZCZijie Chen
Zijie Chen
XSXiaoli Shen
Xiaoli Shen
ZYZhen Yu
Zhen Yu
NFNing Fan
Ning Fan
Introduction The use of the neodymium:yttrium–aluminum-garnet (Nd:YAG) laser to treat malignant glaucoma (MG) has been described in the literature since the 1980s. However, the technique has been reported to have a short-term effect, with a notable relapse rate. In the present study, we report the efficacy and durability of a modified Nd:YAG laser treatment methodology for treatment of pseudophakic or aphakic MG. Methods Patients with chronic angle-closure glaucoma and deemed at high risk of developing post-operative MG received prophylactic peripheral iridectomy during their conventional operation beginning in 2017. When the diagnosis of pseudophakic or aphakic MG was confirmed, a thorough Nd:YAG laser capsulo/zonulo-hyaloido-vitreolysis (CZHV) was performed through iridectomy, along with standardized pre- and post-laser medications. This retrospective case series includes 14 eyes of 11 patients with MG who had surgical preset iridectomy and modified Nd:YAG laser CZHV between 2017 and 2022. Outcome measures included resolution and recurrence of MG and incidence of treatment complications. Results The mean follow-up was 27.1 ± 15.0 months (range, 12–48). Long-term resolution of MG was obtained in all included eyes at the end of the follow-up. Six eyes (42.9%) achieved long-term resolution with a single Nd:YAG laser intervention. Eight eyes (57.1%) achieved long-term resolution following two to three laser interventions, with two eyes (14.3%) experiencing recurrence. There was no complication during the follow-up. At the final visit, a significant reduction (P = 0.0001) in the mean intraocular pressure (IOP) was observed (13.1 ± 2.8 mmHg) compared to presentation (21.4 ± 6.3 mmHg). Conclusion The modified Nd:YAG laser treatment methodology is a minimally invasive option to manage pseudophakic or aphakic MG with sustained effectiveness. Reduced inflammatory reactions due to prophylactic peripheral iridectomy, rapid diagnosis, and timely treatment initiation have all contributed to the favorable outcomes associated with this modified treatment methodology.

27 February 2026 in BMC Public Health
Verified
Journal Article
Open access
PDF file
AJAixia Jin
Aixia Jin
RZRong Zhang
Rong Zhang
XFXinran Fan
Xinran Fan
FLFurong Li
Furong Li
YFYanting Feng
Yanting Feng
NFNing Fan
Ning Fan
To explore the associations between three accelerometer-derived moderate-to-vigorous physical activity (MVPA) patterns and the risk of dry eye disease (DED